A Review of Health Outcomes in Patients with Psoriasis

Dermatologic Clinics

Volumn 30, Issue 1, 2012, Pages 61-72

  Li, Kai ^a   Armstrong, April W ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Health outcomes; Psoriasis; Resources; Treatments

Indexed keywords

ADALIMUMAB; ALEFACEPT; BETAMETHASONE; CALCIPOTRIOL; CORTICOSTEROID; CYCLOSPORIN; EFALIZUMAB; ETANERCEPT; ETRETIN; INFLIXIMAB; LIPID; LIPOPROTEIN; METHOTREXATE; PLACEBO; SALICYLIC ACID; TACROLIMUS; TAZAROTENE; USTEKINUMAB;

ABDOMINAL OBESITY; ACNE; ADL DISABILITY; AGE; ALCOHOL ABUSE; BIOLOGICAL THERAPY; BODY SURFACE; BONE MARROW SUPPRESSION; BURNING SENSATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COMORBIDITY; COST EFFECTIVENESS ANALYSIS; DEPRESSION; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENCY; EPIDERMAL ATROPHY; ERYTHEMA; ERYTHRODERMIC PSORIASIS; GUTTATE PSORIASIS; HEADACHE; HEALTH CARE COST; HEALTH CARE QUALITY; HEALTH STATUS; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INCIDENCE; INJECTION SITE STINGING; KIDNEY FUNCTION; LIFESTYLE MODIFICATION; LIPID BLOOD LEVEL; LONG TERM CARE; MALAISE; MALIGNANT NEOPLASTIC DISEASE; MENTAL STRESS; MONOTHERAPY; NAUSEA; ONSET AGE; PHOTOTHERAPY; PNEUMONIA; PREVALENCE; PRIORITY JOURNAL; PRURITUS; PSORIASIS; PSORIASIS SEVERITY INDEX; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; PSYCHOTHERAPY; PUSTULAR PSORIASIS; PUVA; QUALITY OF LIFE; REVIEW; RHINOPHARYNGITIS; SELF ESTEEM; SEX; SEXUAL BEHAVIOR; SIDE EFFECT; SKIN ALLERGY; SKIN DISEASE; SKIN IRRITATION; SMOKING HABIT; SOCIAL STIGMA; SOCIAL SUPPORT; SPONTANEOUS ABORTION; SUICIDAL IDEATION; SYSTOLIC BLOOD PRESSURE; TREATMENT CONTRAINDICATION; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TREMOR; UPPER RESPIRATORY TRACT INFECTION; UREA NITROGEN BLOOD LEVEL;

DELIVERY OF HEALTH CARE; DERMATOLOGY; HUMANS; INCIDENCE; OUTCOME ASSESSMENT (HEALTH CARE); PREVALENCE; PSORIASIS; SEVERITY OF ILLNESS INDEX; UNITED STATES;

EID: 82455209465     PISSN: 07338635     EISSN: 15580520     Source Type: Journal    
DOI: 10.1016/j.det.2011.08.012     Document Type: Review

References (112)

1. Neimann A.L., Gelfand J.M. The epidemiology of psoriasis. Expert Rev Dermatol 2006, 1(1):63-75.
2. Freedberg I. Fitzpatrick's dermatology in general medicine 2003, McGraw-Hill, New York. 6th edition.
3. Schon B.W. Psoriasis. N Engl J Med 2005, 352:1899-1912.
4. Sander H.M., Morris L.F., Phillips C.M., et al. The annual cost of psoriasis. J Am Acad Dermatol 1993, 28:422-425.
5. Ferrandiz C., Pujol R.M., Garcia-Patos V., et al. Psoriasis of early and late onset: a clinical and epidemiologic study from Spain. J Am Acad Dermatol 2002, 46(6):867-873.
6. De Korte J., Sprangers M.A., Mombers F.M., et al. Quality of life in patients with psoriasis: a systemic literature review. J Investig Dermatol Symp Proc 2004, 9(2):140-147.
7. Stern R.S., Nijsten T., Feldman S.R., et al. Psoriasis is common, carries a substantial burden even when not extensive and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc 2004, 9:136-139.
8. Fowler J.F., Duh M.S., Rovba L., et al. The impact of psoriasis on health care costs and patient work loss. J Am Acad Dermatol 2008, 59(5):772-780.
9. Javitz H.S., Ward M.M., Farber E., et al. The direct cost of care for psoriasis and psoriatic arthritis in the United States. J Am Acad Dermatol 2002, 46(6):850-860.
10. Yu A.P., Tang J., Xie J., et al. Economic burden of psoriasis compared to the general population and stratified by disease severity. Curr Med Res Opin 2009, 25(10):2429-2438.
11. Koo J. Population based epidemiologic study of psoriasis with emphasis on quality of life assessment. Dermatol Clin 1996, 14(3):485-496.
12. Gelfand J.M., Feldman S.R., Stern R.S., et al. Determinants of quality of life in patients with psoriasis: a study from the US population. J Am Acad Dermatol 2004, 51(5):704-708.
13. Kreuger G.K., Koo J., Lebwohl M., et al. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol 2001, 137(3):280-284.
14. McHenry P.M., Doherty V. Psoriasis: an audit of patients' views on the disease and its treatment. Br J Dermatol 1992, 127(1):13-17.
15. Gupta M.A., Gupta A.K., Watteel G.N. Perceived deprivation of social touch in psoriasis is associated with greater psychologic morbidity: an index of the stigma experience in dermatologic disorders. Cutis 1998, 61(6):339-342.
16. Horn E.J., Fox K.M., Patel V., et al. Association of patient-reported psoriasis severity with income and employment. J Am Acad Dermatol 2007, 57(6):963-971.
17. Gupta M.A., Gupta A.K. Psoriasis and sex: a study of moderately to severely affected patients. Int J Dermatol 1997, 36(4):259-262.
18. Ramsay B., O'Reagan M. A survey of the social and psychological effects of psoriasis. Br J Dermatol 1988, 118(2):195-201.
19. Gottlieb A., Chao C., Dann F. Psoriasis comorbidities. J Dermatolog Treat 2008, 19:5-21.
20. Kimball A.B., Gladman D., Gelfand J.M., et al. National psoriasis foundation clinical consensus on psoriasis comorbidities and recommendations for screening. J Am Acad Dermatol 2008, 58:1031-1042.
21. Schiepers O.J., Wichers M.C., Maes M. Cytokines and major depression. Prog Neuropsychopharmacol Biol Psychiatry 2005, 29:201-217.
22. Chodorowska G., Wojnowska D., Juszkiewicz-Borowiec M. Reactive protein and alpha2-macroglobulin plasma activity in medium-severe and severe psoriasis. J Eur Acad Dermatol Venereol 2004, 18:180-183.
23. Gupta M.A., Gupta A.K. Depression and suicidal ideation in dermatology patients with acne, alopecia areata, atopic dermatitis and psoriasis. Br J Dermatol 1998, 139(5):846-850.
24. Esposito M., Saraceno R., Guinta A., et al. An Italian study on psoriasis and depression. Dermatology 2006, 212:123-127.
25. Van Voorhees A.S., Fried R. Depression and quality of life in psoriasis. Postgrad Med 2009, 121(4):154-161.
26. Kurd S.K., Troxel A.B., Crtis-Chritsoph P., et al. The risk of depression, anxiety and suicidality in patients with psoriasis. Arch Dermatol 2010, 146(8):891-895.
27. Schmitt J., Ford D.E. Psoriasis is independently associated with psychiatric morbidity and adverse cardiovascular risk factors, but not with cardiovascular events in a population-based sample. J Eur Acad Dermatol Venereol 2010, 24(8):885-892.
28. Gladman D.D. Psoriatic arthritis. Dermatol Ther 2004, 17:350-363.
29. Torre Alono J.C., Rodriguez Perez A., Arribas Castrillo J.M. Psoriatic arthritis (PA): a clinical, immunological and radiological study of 180 patients. Br J Dermatol 1991, 30:245-250.
30. McDonald C.J., Calabresi P. Complication of psoriasis. JAMA 1973, 224:629.
31. Henseler T., Christophers E. Disease concomitance in psoriasis. J Am Acad Dermatol 1995, 32:982-986.
32. Mallbris L., Akre O., Granath F., et al. Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients. Eur J Epidemiol 2004, 19:225-230.
33. Herron M.D., Hinckley M., Hoffman M.S., et al. Impact of obesity and smoking on psoriasis presentation and management. Arch Dermatol 2005, 141(1):1527-1534.
34. Gelfand J.M., Neimann A.I., Shin D.B., et al. Risk of myocardial infarction in patients with psoriasis. JAMA 2006, 296(14):1735-1741.
35. Neimann A.L., Shin D.B., Wang X. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol 2006, 55:829-835.
36. Mallbris L., Granath F., Hamsten A., et al. Psoriasis is associated with lipid abnormalities at the onset of skin disease. J Am Acad Dermatol 2006, 54:614-621.
37. Akhyani M., Ehsani A.H., Robati R.M., et al. The lipid profile in psoriasis: a controlled study. J Eur Acad Dermatol Venereol 2007, 21:1330-1332.
38. Grundy S.M., Cleeman J.I., Daniels S.R., et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung and Blood Institute Scientific Statement. Circulation 2005, 112:2735-2752.
39. Love T.J., Qureshi A.A., Karlson E.W., et al. Prevalence of the metabolic syndrome in psoriasis: results from the National Health and Nutrition Examination Survey, 2003-2006. Arch Dermatol 2011, 147(4):419-424.
40. Laaksonen D.E., Laaka H.M., Niskanen L.K., et al. Metabolic syndrome and development of diabetes mellitus: application and validation of recently suggested definitions of the metabolic syndrome in a prospective cohort study. Am J Epidemiol 2002, 156:1070-1077.
41. Isomaa B., Almgren P., Tuomi T., et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001, 24:683-689.
42. Margolis D., Biker W., Hennessy S., et al. The risk of malignancy associated with psoriasis. Arch Dermatol 2001, 137:778-783.
43. Frentz G., Olsen J.H. Malignant tumours and psoriasis: a follow-up study. Br J Dermatol 1999, 140:237-242.
44. Boffetta P., Gridley G., Lindelof B. Cancer risk in a population-based cohort of patients hospitalized for psoriasis in Sweden. J Invest Dermatol 2001, 117:1531-1537.
45. Paul C.F., Ho V.C., McGeown C., et al. Risk of malignancies in psoriasis patients treated with cyclosporine: a 5 y cohort study. J Invest Dermatol 2003, 120:211-216.
46. Stern R.S., Nichols K.T., Vakeva L.H. Malignant melanoma in patients treated for psoriasis with methoxsalen (psoralen) and ultraviolet A radiation (PUVA). The PUVA Follow-up Study. N Engl J Med 1997, 336(15):1041-1045.
47. Gerdes S., Mrowietz U. Impact of comorbidities on the management of psoriasis. Management of psoriasis 2009, vol. 38:21-26. Karger, Basel (Switzerland). N. Yawalkar (Ed.).
48. Farber E.M., Nall L. Psoriasis and alcoholism. Cutis 1994, 53(1):21-27.
49. Higgins E.M., Du Vivier A.W. Alcohol abuse and treatment resistance in skin disease. J Am Acad Dermatol 1994, 30(6):1048.
50. Wolf R., Wolf D., Ruocco V. Alcohol intake and psoriasis. Clin Dermatol 1999, 17(4):423-430.
51. Quereshi A.A., Dominguez P.L., Choi H.K., et al. Alcohol intake and risk of incident psoriasis in US women: a prospective study. Arch Dermatol 2010, 146(12):1364-1369.
52. Fortes C., Mastroeni S., Leffondre K., et al. Relationship between smoking and clinical severity of psoriasis. Arch Dermatol 2005, 141(12):1580-1584.
53. Hayes J., Koo J. Psoriasis: depression, anxiety, smoking and drinking habits. Dermatol Ther 2010, 23(2):174-180.
54. Fortune D.G., Richards H.L., Kirby B., et al. A cognitive-behavioural symptom management programme as an adjunct in psoriasis therapy. Br J Dermatol 2002, 146(3):458-465.
55. Weinsterin G.D., Menter M.A. An overview of psoriasis. Therapy of moderate-to-severe psoriasis 2003, 1-28. Mercel Dekker, Inc, New York. G.D. Weinstein, A.B. Gottlieb (Eds.).
56. Drake L.A., Ceilley R.I., Cornelison R.L., et al. Guidelines of care for psoriasis. J Am Acad Dermatol 1993, 28:632-637.
57. Brown B.C., Warren R.B., Grindlay D.J., et al. What's new in psoriasis? Analysis of the clinical significance of systematic reviews on psoriasis published in 2007 and 2008. Clin Exp Dermatol 2009, 34:664-667.
58. Koo J. Sequential therapy of psoriasis. Introducing a new therapeutic paradigm for better clinical results. J Am Acad Dermatol 1999, 41:S25-S28.
59. Kreuger G. Current concepts and review of alefacept in the treatment of psoriasis. Dermatol Clin 2004, 22:407-426.
60. Wahl A., Loge J.H., Wiklund I., et al. The burden of psoriasis: a study concerning health-related quality of life among Norwegian adult patients with psoriasis compared with general population norms. J Am Acad Dermatol 2000, 43(5 Pt 1):803-808.
61. Katz H.I., Hien N.T., Prawer S.E., et al. Superpotent topical steroid treatment of psoriasis vulgaris-clinical efficacy and adrenal function. J Am Acad Dermatol 1987, 16(4):804-811.
62. Tristani-Firouzi P., Kreuger G.G. Efficacy and safety of treatment modalities for psoriasis. Cutis 1998, 61(Suppl 2):11-21.
63. Pariser D.M., Bagel J., Gelfand J.M., et al. National Psoriasis Foundation clinical consensus on disease severity. Arch Dermatol 2007, 143:239-242.
64. Kreuger C.G., Feldman S.R., Camisa C. Two considerations for patients with psoriasis and their clinicians: what defines mild, moderate, and severe psoriasis?. J Am Acad Dermatol 2000, 43(2 Pt 1):281-285.
65. Gower W.R. Mechanism of glucocorticoid action. J Fla Med Assoc 1993, 80(10):697-700.
66. Cornell R.C. Clinical trials of topical corticosteroids in psoriasis: correlations with the vasoconstrictor assay. Int J Dermatol 1992, 31(Suppl 1):38-40.
67. Gibson J.R., Kirsch J.M., Darley C.R., et al. An assessment of the relationship between vasoconstrictor assay findings, clinical efficacy and skin thinning effects of a variety of undiluted and diluted corticosteroid preparations. Br J Dermatol 1984, 111(Suppl 27):204-212.
68. Levin C., Maibach H.I. Topical corticosteroid-induced adrenocortical insufficiency: clinical implications. Am J Clin Dermatol 2002, 3(3):141-147.
69. Georgiou S., Tsambaos D. Hypercalcaemia and hypercalciuria after topical treatment of psoriasis with excessive amounts of calcipotriol. Acta Derm Venereol 1999, 79(1):86.
70. Yamauchi P.S., Rizk D., Kormili T., et al. Systemic retinoids. Therapy of moderate-to-severe psoriasis 2003, 137-150. Marcel Dekker, Inc, New York. G.D. Weinstein, A.B. Gottlieb (Eds.).
71. Lebwohl M., Ast E., Callen J.P., et al. Once-daily tazarotene gel versus twice-daily fluocinonide cream in the treatment of plaque psoriasis. J Am Acad Dermatol 1998, 38(5 Pt 1):705-711.
72. Vissers W.H., Van Vlijmen I., Van Erp P.E., et al. Topical treatment of mild to moderate plaque psoriasis with 0.3% tacrolimus gel and 0.5% tacrolimus cream: the effect on SUM score, epidermal proliferation, keratinization, T-cell subsets and HLA-DR expression. Br J Dermatol 2008, 158(4):705-712.
73. Zonneveld I.M., Rubins A., Jablonska S., et al. Topical tacrolimus is not effective in chronic plaque psoriasis: a pilot study. Arch Dermatol 1998, 134:1101-1102.
74. Remitz A., Reitamo S., Erkko P., et al. Tacrolimus ointment improves psoriasis in microplaque assay. Br J Dermatol 1999, 141:103-107.
75. Clayton T.H., Harrison P.V., Nicholls R., et al. Topical tacrolimus for facial psoriasis. Br J Dermatol 2003, 149:419-420.
76. Stern R.S. The risk of melanoma in association with long-term exposure to PUVA. J Am Acad Dermatol 2001, 44:755-761.
77. Hanseler T., Christophers E., Honigsmann H., et al. Skin tumors in the European PUVA study. J Am Acad Dermatol 1987, 16:108-116.
78. Stern R.S., Thibodeau L.A., Kleinerman R.A., et al. Risk of cutaneous carcinoma in patients treated with oral methoxsalen photochemotherapy for psoriasis. N Engl J Med 1979, 300:809-813.
79. Marcil I., Stern R.S. Squamous cell cancer of the skin in patients given PUVA and cyclosporin: nested cohort crossover study. Lancet 2001, 358:1042-1045.
80. Lindelof B., Siguirgeirsson B., Tegner E., et al. PUVA and cancer: a large-scale epidemiological study. Lancet 1991, 338(8759):91-93.
81. Lee E., Koo J., Berger T. UVB phototherapy and skin cancer risk: a review of the literature. Int J Dermatol 2005, 44(5):355-360.
82. Torinuki W., Tagami H. Incidence of skin cancer in Japanese psoriatic patients treated with either methoxsalen phototherapy, Goeckerman regimen, or both therapies. A 10-year follow-up study. J Am Acad Dermatol 1988, 18(6):1278-1281.
83. Coven T.R., Burack L.H., Gillaeudeau P., et al. Narrowband UVB produces superior clinical and histopathological resolution of moderate-to-severe psoriasis in patients compared with broadband UVB. Arch Dermatol 1997, 133:1514-1522.
84. Van Dooren-Greebe R.J., Kiujpers A.L., Mulder J., et al. Methotrexate revisited: effects of long-term treatment in psorasis. Br J Dermatol 1994, 130(2):204-210.
85. Roenigk H.H., Auerbach R., Maibach H.I., et al. Methotrexate guidelines revised. J Am Acad Dermatol 1982, 6:145-155.
86. Roenigk H.H., Auerbach R., Maibach H.I., et al. Methotrexate in psoriasis: consensus conference. J Am Acad Dermatol 1998, 38:478-485.
87. Otley C.C., Stasko T., Tope W.D., et al. Chemoprevention of nonmelanoma skin cancer with systemic retinoids: practical dosing and management of adverse effects. Dermatol Surg 2006, 32:562-568.
88. Ellis C.N., Fradin M.S., Messana J.M., et al. Cyclosporine for plaque-type psoriasis. Results of a multidose, double-blind trial. N Engl J Med 1991, 324(5):277-284.
89. Shupack J., Abel E., Bauer E., et al. Cyclosporine as maintenance therapy in patients with severe psoriasis. J Am Acad Dermatol 1997, 36:423-432.
90. Mahrle G., Schulze H.J., Farber L., et al. Low-dose short-term cyclosporine versus etretinate in psoriasis: improvement of skin, nail and join involvement. J Am Acad Dermatol 1995, 32:78-88.
91. Ho V.C., Griffiths C.E., Berth-Jones J., et al. Intermittent short courses of cyclosporine microemulsion for the long-term management of psoriasis: a 2-year cohort study. J Am Acad Dermatol 2001, 44:643-651.
92. Bahner J.D., Cao L.Y., Korman N.J. Biologics in the management of psoriasis. Clin Cosmet Investig Dermatol 2009, 2:111-128.
93. Weinberg J.M. An overview of infliximab, etanercept, efalizumab, and alefacept as biologic therapy for psoriasis. Clin Ther 2003, 25(10):2487-2505.
94. Menter A., Tyring S.K., Gordon K., et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol 2008, 58(1):106-115.
95. Scallon B., Cai A., Solowski N., et al. Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther 2002, 301(2):418-426.
96. Schmitt J., Zhang Z., Wozel G., et al. Efficacy and tolerability of biologic and nonbiologic systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials. Br J Dermatol 2008, 159(3):513-526.
97. Desai S.B., Furst D.E. Problems encountered during anti-tumor necrosis factor therapy. Best Pract Res Clin Rheumatol 2006, 20(4):757-790.
98. Langley R.G., Strober B.E., Gu Y., et al. Benefit-risk assessment of tumour necrosis factor antagonists in the treatment of psoriasis. Br J Dermatol 2010, 162(6):1349-1358.
99. Lebwohl M., Christophers E., Langley R., et al. An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch Dermatol 2003, 139(6):719-727.
100. Ellis C.N., Krueger G.G. Alefacept Clinical Study Group. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med 2001, 345(4):248-255.
101. Griffiths C.E.M., Stroker B.E., Van de Kerkhof P., et al. Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis. N Engl J Med 2010, 362:118-128.
102. Stelara safety information. Available at: 2010. Accessed February 10, 2011. http://www.stelarainfo.com.
103. Iest J., Boer J. Combined treatment of psoriasis with acitretin and UVB phototherapy compared with acitretin alone and UVB alone. Br J Dermatol 1989, 120:665-670.
104. Lebwohl M. Acitretin in combination with UVB or PUVA. J Am Acad Dermatol 1999, 41(3 Pt 2):S22-S24.
105. Lowe N., Prystowsky J.H., Bourget T., et al. Acitretin plus UVB therapy for psoriasis: comparisons with placebo plus UVB and acitretin alone. J Am Acad Dermatol 1991, 24:591-594.
106. Spuls P.I., Lebwohl M. Retrospective study of the efficacy of narrowband UVB and acitretin. J Dermatolog Treat 2003, 14(Suppl 2):17-20.
107. Tanew A., Guggenbichler A., Honigsmann H., et al. Photochemotherapy for severe psoriasis without or in combination with acitretin: a randomized, double-blind comparison study. J Am Acad Dermatol 1991, 26:682-684.
108. Kragballe K., Van de Kerhof P.C. Consistency of data in six phase III clinical studies of a two-compound product containing calcipotriol and betamethasone dipropionate ointment for the treatment of psoriasis. J Eur Acad Dermatol Venereol 2006, 20(1):39-44.
109. Rim J.H., Paark J.Y., Choe Y.B., et al. The efficacy of calcipotriol and acitretin combination therapy for psoriasis. Am J Clin Dermatol 2003, 4(7):507-510.
110. Pearce D.J., Nelson A.A., Fleischer A.B., et al. The cost-effectiveness and cost of treatment failures associated with systemic psoriasis therapies. J Dermatolog Treat 2006, 17:29-37.
111. Available at: 2010. Accessed February 15, 2011. http://www.decisionresources.com.
112. Referral Guide. Psoriasis. In: Dermatology AAO, editor. Indications for dermatology referrals in a managed care setting. Schaumburg (IL): American Academy of Dermatology; 2009.